2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uribarri, J. Articles by Vlassara, H. Search for Related Content PubMed PubMed Citation Articles by Uribarri, J. Articles by Vlassara, H.

Restriction of Dietary Glycotoxins Reduces Excessive Advanced Glycation End Products in Renal Failure Patients

Jaime Uribarri, Melpomeni Peppa^*, Weijing Cai^*, Teresia Goldberg^*, Min Lu^*, Cijiang He and Helen Vlassara^*

Division of Experimental Diabetes and Aging, *Department of Geriatrics, and Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, New York.

Correspondence to Dr. Jaime Uribarri, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029. Phone: 212-241-1887; Fax: 212-369-9330;

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
ABSTRACT. Advanced glycation endproduct (AGE) levels are elevated in renal failure patients and may contribute to the excessive cardiovascular disease in this population. Diet-derived AGE are major contributors to the total body AGE pool. It was postulated that a reduction in dietary AGE intake might impact on the high circulating AGE levels in renal failure patients. Twenty-six nondiabetic renal failure patients on maintenance peritoneal dialysis were randomized to either a high or a low AGE diet for 4 wk. Three-day dietary records, fasting blood, 24-h urine, and dialysis fluid collections were obtained at baseline and end of study. AGE levels were determined by ELISA for N-carboxymethyl-lysine (CML) and methylglyoxal-derivatives (MG). Eighteen patients completed the study. Low dietary AGE intake decreased serum CML (34%; P < 0.002), serum MG (35%; P < 0.008), CML-LDL (28%; P < 0.011), CML-apoB (25%; P < 0.028), dialysate CML (39%; P < 0.03), and dialysate MG output (40%; P < 0.04). High dietary AGE intake increased serum CML (29%; P < 0.028), serum MG (26%; P < 0.09), CML-LDL (50%; P < 0.011), CML-apoB (67%; P < 0.028), and dialysate CML output (27%; P < 0.01). Serum AGE correlated with BUN (r = 0.6, P < 0.002 for CML; r = 0.4, P < 0.05 for MG), serum creatinine (r = 0.76, P < 0.05 for CML; r = 0.55, P < 0.004 for MG), total protein (r = 0.4, P < 0.05 for CML; r = 0.4, P < 0.05 for MG), albumin (r = 0.4, P < 0.02 for CML; r = 0.4, P < 0.05 for MG), and phosphorus (r = 0.5, P < 0.006 for CML; r = 0.5, P < 0.01 for MG). It is concluded that dietary glycotoxins contribute significantly to the elevated AGE levels in renal failure patients. Moreover, dietary restriction of AGE is an effective and feasible method to reduce excess toxic AGE and possibly cardiovascular associated mortality. E-mail: jaime.uribarri@mssm.edu

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Elevated circulating levels of advanced glycation end products (AGE) are found in renal failure patients undergoing dialysis, irrespective of the presence of diabetes (1). There is an extensive literature on the relationship between circulating AGE and atherosclerotic disease (2). Cardiovascular disease is the main cause of morbidity and mortality among dialysis patients, and only part of this increased risk can be explained by traditional risk factors (3). The suggestion has been made that uremia and/or dialysis-specific factors, including high body burden of AGE, may play a role as cardiovascular risk factors (1,2). It thus becomes clinically important to elucidate potential mechanisms for the AGE elevation to develop efficient therapies.

Increased AGE burden in renal failure patients has been attributed to either decreased renal clearance or increased endogenous formation of these compounds due to the elevated oxidant stress observed in uremia (4). Recently, it has been recognized that diet constitutes an important source of exogenous AGE (5,6). Dietary AGE content clearly depends on the nutrient composition and on the way food is processed (5,7). Modulation of oral AGE intake in human subjects or animals with or without diabetes or renal disease has been shown to modify circulating AGE levels, supporting the view that dietary AGE intake is an important contributor to the body AGE pool (6,8,9).

We postulated that the ingestion of pre-formed dietary AGE contributes significantly to the high circulating AGE levels in nondiabetic renal failure patients. To test this hypothesis, we studied a cohort of ambulatory chronic peritoneal dialysis patients without diabetes and measured circulating AGE levels before and after randomization to either a high or a low AGE content diet.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patients and Design
This was a prospective and randomized 4-wk study. The study protocol was approval by the IRB at Mount Sinai Medical Center, New York. Twenty-six adult, stable nondiabetic peritoneal dialysis patients from this institution were recruited. None of the medications or dialysis prescriptions were modified as part of the study. Any changes that took place during the study were based on independent clinical evaluation of patients. The peritoneal dialysis fluid used was Dianeal (Baxter, Illinois) containing 40 mmol/L of lactate and a variable concentration of dextrose. Fasting venous blood, a 24-h urine, a 24-h dialysate collection, and a log containing a detailed 3-d dietary history were obtained at baseline and at the end of study.

Patients had an initial interview with the research dietitian and were then randomized to either a high (H-AGE) or low AGE (L-AGE) diet. Subjects were individually instructed on meal planning to meet study requirements while maintaining their usual peritoneal dialysis diet instructions. To vary the AGE content, foods, particularly meat, were exposed to different cooking methods. L-AGE subjects were instructed to boil, poach, stew or steam, avoid fried entrees, and reheat food indirectly using steam in a double boiler. H-AGE participants were instructed to roast, broil and oven fry foods as usual. For both arms, written instructions and recipes were provided. The subjects were followed closely by phone calls (1 to 2 times/wk) to assure dietary compliance. Food composition from the 3-d logs was analyzed by using a nutrient software program (Food Processor version 7.1, Salem, Oregon). Dietary AGE intake was estimated by using an AGE score system, based on a database of 250 foods (9), and expressed as AGE kilounits (kU) per gram of food, whereby 1000 AGE kU were scored as 1 point AGE.

Laboratory Procedures
All routine biochemical parameters in blood, urine, and dialysate fluid were measured in the hospital clinical laboratory by standard methods. Serum, plasma, urine, and dialysate AGE were determined by ELISA using an N-carboxymethyl-lysine sensitive monoclonal anti-AGE-KLH antibody (CML) and a monoclonal anti-MG-BSA antibody (MG) as described previously (9).

The 24-h urine and dialysate collections allowed the calculation of weekly urea Kt/V (an index of dialysis adequacy), normalized protein catabolic rate (nPCR; an index of protein intake), and peritoneal dialysis daily glucose absorption by standard formulas, as described before (10).

Statistical Analyses
All data are given as mean ± SEM. Differences of means between the two dietary groups were analyzed by the Mann-Whitney U unpaired test. Univariate correlation analyses were examined by Spearman correlation coefficient. Stepwise multiple regression analysis was performed to assess variables that were independently associated with dietary AGE intake. Statistically significant difference was defined as P 0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
We recruited and obtained baseline measurements in 26 patients. Eight of the 26 patients (four on L-AGE and four on H-AGE groups) did not complete the study: three developed complications unrelated to the study (persistent GI bleeding, acute myocardial infarction, and severe peritonitis). Another five patients did not respond to the dietitian phone calls to assess dietary compliance and did not show up for the follow up visit. Eighteen randomized subjects completed the study: nine subjects (six women and three men) in the H-AGE diet and nine subjects (six women and three men) in the L-AGE diet.

At baseline and at the end of study, there were no statistically significant differences between diet groups in terms of age, weight, BMI, time on peritoneal dialysis, weekly urea Kt/V, or any routine biochemical parameter.

There were no statistically significant differences between baseline and the end of study in each group or between groups in terms of peritoneal dialysate volume inflow (10 versus 9.8 L/d in the L-AGE group; 10.8 versus 10.9 L/d in the H-AGE group), peritoneal dialysate fluid glucose inflow (230 versus 220 g/d in the L-AGE group; 236 versus 243 g/d in the H-AGE group), and peritoneal glucose load received by the patient (142 versus 135 g/d in the L-AGE group; 122 versus 139 g/d in the H-AGE group).

Dietary changes between baseline and end of the experimental periods, as estimated by 3-d dietary records are shown in Table 1.

View larger version (21K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. Serum advanced glycation endproduct (AGE) levels in peritoneal dialysis patients exposed to high- and low-AGE diet. At baseline and after 4-wk exposure to either high (H-AGE) or low-AGE (L-AGE) diet, fasting serum samples were tested for AGE using ELISA for N-carboxymethyl-lysine (CML; panel A) and MG-derivatives (MG; panel B). *Statistically significant difference between baseline and end of study in each group (P 0.05). # Statistically significant difference at the end of study between the two groups (P 0.05). Data are shown as means ± SEM.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The current study indicates that even short-term modifications of dietary AGE intake can significantly alter circulating AGE levels in renal failure patients on maintenance peritoneal dialysis. These findings support the hypothesis that exogenous glycotoxins derived from common diets, including those recommended for dialysis patients, play a significant role in maintaining high circulating AGE levels in uremia.

There is extensive experimental evidence from animal studies showing significant changes in circulating AGE levels as a result of dietary AGE modulations (6,8,9). Recently, it has been shown that circulating AGE levels decreased after dietary AGE restriction in diabetic patients with normal renal function (9). In the present study, we found a comparable effect of the low AGE intake in nondiabetic subjects with renal failure. In addition, the current group consumed self-selected diets prepared by them at home indicating that these dietary modifications are feasible as an intervention in this population.

The positive correlation between circulating AGE and parameters directly depending on food intake, such as BUN, serum phosphorus, and potassium, further supports the postulation that diet represents an important source for these compounds. The correlation of circulating AGE with nutritional indicators such as serum total protein, albumin, and creatinine supports the notion that AGE may prove useful as markers of nutritional status.

The simultaneous and parallel changes in circulating, urinary, and dialysate AGE levels were most likely attributable to diet, as other potentially confounding factors were eliminated. Diabetic patients were excluded, the daily amount of glucose absorbed during peritoneal dialysis did not differ significantly between baseline and experimental periods, and blood glucose and lipid levels did not change during the study period. Moreover, there was no obvious evidence for any independent changes in the oxidative state to influence AGE levels in these patients. Although not tested, a reduction in serum inflammatory markers was found in response to the same low AGE diet in diabetic patients (9), suggesting that a similar effect may have occurred in the current patients.

The feasibility of an intervention that lowers circulating AGE levels in renal failure patients should be appealing to clinicians in view of the extremely high mortality from cardiovascular disease in this population (3), the experimentally proven toxicity of AGE (1), and the ineffectiveness of available therapy. Although a large body of data suggests strongly that circulating AGE may be an important cardiovascular risk factor in renal failure (1,2), a recent clinical study (11) showed a negative correlation between serum CML levels and cardiovascular mortality in dialysis patients indicating the need for further studies.

AGE can also be generated in the peritoneal cavity during peritoneal dialysis (12). The fact that changes in circulating and dialysate AGE levels followed in parallel the changes in dietary AGE, while peritoneal dialysis prescription remained unchanged, suggests that the magnitude of intraperitoneal production of AGE is relatively modest.

Changes in peritoneal membrane function associated with changes in serum and dialysate AGE have been described (13), but the short duration of our study made any such changes unlikely.

In conclusion, dietary restriction of AGE may prove a reasonable method to reduce the excessive burden of toxic AGE in vital tissues and presumably the morbidity and mortality associated with their accumulation. In addition, this short-term study shows that this intervention is feasible in renal failure patients. Although the current intervention dealt exclusively with chronic peritoneal dialysis patients, these findings should be applicable to patients on hemodialysis or to chronic renal failure patients in general.

	Acknowledgments

 
We are grateful to Frine Dimaano, RD and the Nursing Staff of the Mount Sinai Hospital Peritoneal Dialysis Program for their valuable assistance throughout this project. This work was funded by the National institute of Health (DK/AG 54788 to H.V.)

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Raj DSC, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: a nephrologist’s perspective. Am J Kid Dis 35: 365–380, 2000[Medline]
2. Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Intern Med 251: 87–101, 2002[CrossRef][Medline]
3. Ma KW, Greene EL, Raji L: Cardiovascular risk factors in chronic renal failure and hemodialysis population. Am J Kidney Dis 19: 505–513, 1992[Medline]
4. Weiss MF, Erhard P, Kader-Attia FA, Wu YC, DeOreo PB, Araki A, Glomb MA, Monnier VM: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57: 2571–2585, 2000[CrossRef][Medline]
5. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive advanced glycation end products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94: 6474–6479, 1997[Abstract/Free Full Text]
6. Cai W, Cao Q, Zhu l, Peppa M, He C, Vlassara H: Oxidative stress-induced carbonyl compounds from common foods: Novel mediators of cellular dysfunction. Molecular Medicine 8: 337–346, 2002[Medline]
7. Lee T, Kimiagar M, Pintauro SJ, Chichester CO: Physiological and safety aspects of Maillard browning of foods. Prog Food Nutr Sci 5: 243–256, 1981[Medline]
8. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H: Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 18: 224–237, 2002[CrossRef][Medline]
9. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99: 15596–15601, 2002[Abstract/Free Full Text]
10. Uribarri J, Leibowitz J, Dimaano. Caloric intake in a group of peritoneal dialysis patients. Am J Kid Dis 32: 1–5, 1998[Medline]
11. Schwedler SB, Metzger T, Schinzel R, Wanner C: Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62: 301–310, 2002[CrossRef][Medline]
12. Friedlander MA, Wu YC, Elgawish A, Monnier VM: Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 97: 728–773, 1996[Medline]
13. Parks MS, Lee HA, Chu WS, Yang DW, Hwang SD: Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 20: 452–460, 2000[Abstract/Free Full Text]

This article has been cited by other articles:

				W. Cai, J. C. He, L. Zhu, X. Chen, F. Zheng, G. E. Striker, and H. Vlassara Oral Glycotoxins Determine the Effects of Calorie Restriction on Oxidant Stress, Age-Related Diseases, and Lifespan Am. J. Pathol., August 1, 2008; 173(2): 327 - 336. [Abstract] [Full Text] [PDF]

				H. VLASSARA, J. URIBARRI, W. CAI, and G. STRIKER Advanced Glycation End Product Homeostasis: Exogenous Oxidants and Innate Defenses Ann. N.Y. Acad. Sci., April 1, 2008; 1126(1): 46 - 52. [Abstract] [Full Text] [PDF]

				J. W.L. Hartog, A. A. Voors, C. G. Schalkwijk, J. Scheijen, T. D.J. Smilde, K. Damman, S. J.L. Bakker, A. J. Smit, and D. J. van Veldhuisen Clinical and prognostic value of advanced glycation end-products in chronic heart failure Eur. Heart J., December 1, 2007; 28(23): 2879 - 2885. [Abstract] [Full Text] [PDF]

				J. Uribarri, A. Stirban, D. Sander, W. Cai, M. Negrean, C. E. Buenting, T. Koschinsky, and H. Vlassara Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects Diabetes Care, October 1, 2007; 30(10): 2579 - 2582. [Abstract] [Full Text] [PDF]

				S. Bengmark Advanced Glycation and Lipoxidation End Products-Amplifiers of Inflammation: The Role of Food JPEN J Parenter Enteral Nutr, September 1, 2007; 31(5): 430 - 440. [Abstract] [Full Text] [PDF]

				W. Cai, J. C. He, L. Zhu, X. Chen, S. Wallenstein, G. E. Striker, and H. Vlassara Reduced Oxidant Stress and Extended Lifespan in Mice Exposed to a Low Glycotoxin Diet: Association with Increased AGER1 Expression Am. J. Pathol., June 1, 2007; 170(6): 1893 - 1902. [Abstract] [Full Text] [PDF]

				J. Uribarri, W. Cai, M. Peppa, S. Goodman, L. Ferrucci, G. Striker, and H. Vlassara Circulating Glycotoxins and Dietary Advanced Glycation Endproducts: Two Links to Inflammatory Response, Oxidative Stress, and Aging J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2007; 62(4): 427 - 433. [Abstract] [Full Text] [PDF]

				J. Uribarri and K. R. Tuttle Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1293 - 1299. [Abstract] [Full Text] [PDF]

				A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury Circulation, August 8, 2006; 114(6): 597 - 605. [Abstract] [Full Text] [PDF]

				H. Liu, F. Zheng, Z. Li, J. Uribarri, B. Ren, R. Hutter, J. R. Tunstead, J. Badimon, G. E. Striker, and H. Vlassara Reduced Acute Vascular Injury and Atherosclerosis in Hyperlipidemic Mice Transgenic for Lysozyme Am. J. Pathol., July 1, 2006; 169(1): 303 - 313. [Abstract] [Full Text] [PDF]

				M. A. Roberts, M. C. Thomas, D. Fernando, N. Macmillan, D. A. Power, and F. L. Ierino Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1611 - 1617. [Abstract] [Full Text] [PDF]

				A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]

				O. Sandu, K. Song, W. Cai, F. Zheng, J. Uribarri, and H. Vlassara Insulin Resistance and Type 2 Diabetes in High-Fat-Fed Mice Are Linked to High Glycotoxin Intake Diabetes, August 1, 2005; 54(8): 2314 - 2319. [Abstract] [Full Text] [PDF]

				R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology, July 1, 2005; 15(7): 16R - 28R. [Abstract] [Full Text] [PDF]

				J. W. L. HARTOG, A. P. J. DE VRIES, H. L. LUTGERS, R. MEERWALDT, R. M. HUISMAN, W. J. VAN SON, P. E. DE JONG, and A. J. SMIT Accumulation of Advanced Glycation End Products, Measured as Skin Autofluorescence, in Renal Disease Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 299 - 307. [Abstract] [Full Text] [PDF]

				H. VLASSARA Advanced Glycation in Health and Disease: Role of the Modern Environment Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 452 - 460. [Abstract] [Full Text] [PDF]

				J. URIBARRI, W. CAI, O. SANDU, M. PEPPA, T. GOLDBERG, and H. VLASSARA Diet-Derived Advanced Glycation End Products Are Major Contributors to the Body's AGE Pool and Induce Inflammation in Healthy Subjects Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 461 - 466. [Abstract] [Full Text] [PDF]

				A. FORSTER, Y. KUHNE, and T. HENLE Studies on Absorption and Elimination of Dietary Maillard Reaction Products Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 474 - 481. [Abstract] [Full Text] [PDF]

				K. SEBEKOVA, T. HOFMANN, P. BOOR, K. SEBEKOVA JR., O. ULICNA, H. F. ERBERSDOBLER, J. W. BAYNES, S. R. THORPE, A. HEIDLAND, and V. SOMOZA Renal Effects of Oral Maillard Reaction Product Load in the Form of Bread Crusts in Healthy and Subtotally Nephrectomized Rats Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 482 - 491. [Abstract] [Full Text] [PDF]

				A Heidland, K Sebekova, A Frangiosa, L S De Santo, M Cirillo, F Rossi, M Cotrufo, A Perna, A Klassen, R Schinzel, et al. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation Heart, November 1, 2004; 90(11): 1269 - 1274. [Abstract] [Full Text] [PDF]

				W. Cai, J. C. He, L. Zhu, M. Peppa, C. Lu, J. Uribarri, and H. Vlassara High Levels of Dietary Advanced Glycation End Products Transform Low-Density Lipoprotein Into a Potent Redox-Sensitive Mitogen-Activated Protein Kinase Stimulant in Diabetic Patients Circulation, July 20, 2004; 110(3): 285 - 291. [Abstract] [Full Text] [PDF]

				M. Peppa, H. Brem, P. Ehrlich, J.-G. Zhang, W. Cai, Z. Li, A. Croitoru, S. Thung, and H. Vlassara Adverse Effects of Dietary Glycotoxins on Wound Healing in Genetically Diabetic Mice Diabetes, November 1, 2003; 52(11): 2805 - 2813. [Abstract] [Full Text] [PDF]

				M. Peppa, C. He, M. Hattori, R. McEvoy, F. Zheng, and H. Vlassara Fetal or Neonatal Low-Glycotoxin Environment Prevents Autoimmune Diabetes in NOD Mice Diabetes, June 1, 2003; 52(6): 1441 - 1448. [Abstract] [Full Text] [PDF]

				M. E. Suliman, O. Heimburger, P. Barany, B. Anderstam, R. Pecoits-Filho, E. Rodriguez Ayala, A. R. Qureshi, I. Fehrman-Ekholm, B. Lindholm, and P. Stenvinkel Plasma Pentosidine Is Associated with Inflammation and Malnutrition in End-Stage Renal Disease Patients Starting on Dialysis Therapy J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1614 - 1622. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uribarri, J. Articles by Vlassara, H. Search for Related Content PubMed PubMed Citation Articles by Uribarri, J. Articles by Vlassara, H.